[go: up one dir, main page]

CY1122763T1 - Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων - Google Patents

Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων

Info

Publication number
CY1122763T1
CY1122763T1 CY20201100013T CY201100013T CY1122763T1 CY 1122763 T1 CY1122763 T1 CY 1122763T1 CY 20201100013 T CY20201100013 T CY 20201100013T CY 201100013 T CY201100013 T CY 201100013T CY 1122763 T1 CY1122763 T1 CY 1122763T1
Authority
CY
Cyprus
Prior art keywords
new
imidazopyridazine compounds
disease
pi3k
compounds
Prior art date
Application number
CY20201100013T
Other languages
English (en)
Inventor
Wei-Guo Su
Guangxiu Dai
Weihan Zhang
Wei Deng
Original Assignee
Hutchison Medipharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Limited filed Critical Hutchison Medipharma Limited
Publication of CY1122763T1 publication Critical patent/CY1122763T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα γνωστοποίηση παρέχει νέες ενώσεις ιμιδαζοπυριδαζίνης του τύπου (I) και φαρμακευτικά αποδεκτά άλατα αυτών, φαρμακευτικές συνθέσεις που τις περιέχουν, μία μέθοδο για την παρασκευή τους και την πρακτική τους επίδραση στην αναστολή της ΡΙ3Κ και τη δυνητική χρήση τους στη θεραπευτική αντιμετώπιση μίας ασθένειας που αποκρίνεται στην αναστολή της PΙ3K, για παράδειγμα, μία φλεγμονώδης νόσος, ένα αυτοάνοσο νόσημα ή ο καρκίνος.
CY20201100013T 2014-09-24 2020-01-08 Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων CY1122763T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410494483.5A CN105503877A (zh) 2014-09-24 2014-09-24 咪唑并哒嗪类化合物及其用途
PCT/CN2015/090367 WO2016045591A1 (en) 2014-09-24 2015-09-23 Novel imidazopyridazine compounds and their use

Publications (1)

Publication Number Publication Date
CY1122763T1 true CY1122763T1 (el) 2021-03-12

Family

ID=55580324

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100013T CY1122763T1 (el) 2014-09-24 2020-01-08 Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων

Country Status (33)

Country Link
US (2) US10208066B2 (el)
EP (1) EP3197898B1 (el)
JP (1) JP6381792B2 (el)
KR (2) KR102111570B1 (el)
CN (2) CN105503877A (el)
AR (1) AR101964A1 (el)
AU (1) AU2015320142B2 (el)
BR (1) BR112017006002B1 (el)
CA (1) CA2958671C (el)
CL (1) CL2017000682A1 (el)
CY (1) CY1122763T1 (el)
DK (1) DK3197898T3 (el)
EA (1) EA032643B1 (el)
ES (1) ES2765510T3 (el)
HR (1) HRP20192279T1 (el)
HU (1) HUE047377T2 (el)
IL (1) IL250703B (el)
LT (1) LT3197898T (el)
MX (1) MX2017003902A (el)
MY (1) MY178136A (el)
NZ (1) NZ729886A (el)
PE (1) PE20170936A1 (el)
PH (1) PH12017500564B1 (el)
PL (1) PL3197898T3 (el)
PT (1) PT3197898T (el)
RS (1) RS59831B1 (el)
SG (1) SG11201701545YA (el)
SI (1) SI3197898T1 (el)
SM (1) SMT201900752T1 (el)
TW (1) TWI707855B (el)
UA (1) UA118066C2 (el)
WO (1) WO2016045591A1 (el)
ZA (1) ZA201701312B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503877A (zh) * 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途
CN109516973A (zh) * 2017-09-19 2019-03-26 南京圣和药业股份有限公司 取代嘧啶类化合物、其制备方法及用途
CN110386937A (zh) * 2018-04-20 2019-10-29 和记黄埔医药（上海）有限公司 化合物的晶型和无定型
TWI840477B (en) 2018-12-20 2024-05-01 德商拜耳廠股份有限公司 Heterocyclyl pyridazine as fungicidal compounds
CN110028502B (zh) * 2019-05-29 2020-02-14 济南周行医药科技有限公司 一种激酶抑制剂类药物中间体的制备方法
CA3187297A1 (en) 2020-06-18 2021-12-23 Bayer Aktiengesellschaft Active compound combinations
CN114031558A (zh) * 2021-12-14 2022-02-11 无锡捷化医药科技有限公司 一种1-(6-氯哒嗪-4-基）乙基-1-酮的制备方法
CN118159524B (zh) * 2022-01-28 2024-12-17 和记黄埔医药（上海）有限公司 咪唑并[1,2-b]哒嗪类化合物的中间体的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773958A (en) 1997-01-03 1998-06-30 Ovonic Battery Company, Inc. Apparatus for detecting cell reversal in rechargeable batteries
US6248740B1 (en) 1997-04-25 2001-06-19 Takeda Chemical Industries, Ltd. Condensed pyridazine derivatives, their production and use
CN102229609A (zh) 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
AU2007233709A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds
CN101528748A (zh) * 2006-10-30 2009-09-09 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的咪唑并哒嗪类化合物
MX2009004623A (es) 2006-10-30 2009-05-15 Novartis Ag Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
AR066477A1 (es) 2007-05-09 2009-08-19 Novartis Ag Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
EP2678016B1 (en) * 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
WO2013082540A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
US20150011569A1 (en) * 2011-12-15 2015-01-08 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
ES2685568T3 (es) 2012-12-21 2018-10-10 Gilead Calistoga Llc Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
CN105503877A (zh) * 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途

Also Published As

Publication number Publication date
CN106715432A (zh) 2017-05-24
NZ729886A (en) 2020-06-26
PH12017500564A1 (en) 2017-08-30
KR102006670B1 (ko) 2019-10-01
EP3197898B1 (en) 2019-11-27
BR112017006002A2 (pt) 2017-12-19
LT3197898T (lt) 2020-02-10
KR102111570B1 (ko) 2020-05-18
PT3197898T (pt) 2020-01-17
KR20190090065A (ko) 2019-07-31
EA201790276A1 (ru) 2017-10-31
RS59831B1 (sr) 2020-02-28
EP3197898A1 (en) 2017-08-02
BR112017006002B1 (pt) 2023-02-14
HUE047377T2 (hu) 2020-04-28
EP3197898A4 (en) 2018-03-14
ZA201701312B (en) 2019-06-26
AU2015320142B2 (en) 2018-02-15
ES2765510T3 (es) 2020-06-09
CA2958671A1 (en) 2016-03-31
AU2015320142A1 (en) 2017-04-27
CN106715432B (zh) 2019-03-26
TWI707855B (zh) 2020-10-21
HRP20192279T1 (hr) 2020-03-06
PL3197898T3 (pl) 2020-06-29
SI3197898T1 (sl) 2020-03-31
TW201612181A (en) 2016-04-01
IL250703B (en) 2020-09-30
MY178136A (en) 2020-10-05
SG11201701545YA (en) 2017-04-27
PH12017500564B1 (en) 2020-02-26
PE20170936A1 (es) 2017-07-13
EA032643B1 (ru) 2019-06-28
MX2017003902A (es) 2017-12-07
IL250703A0 (en) 2017-04-30
AR101964A1 (es) 2017-01-25
WO2016045591A1 (en) 2016-03-31
UA118066C2 (uk) 2018-11-12
US20190127391A1 (en) 2019-05-02
JP2017528500A (ja) 2017-09-28
JP6381792B2 (ja) 2018-08-29
DK3197898T3 (da) 2020-01-20
CN105503877A (zh) 2016-04-20
CA2958671C (en) 2019-04-30
SMT201900752T1 (it) 2020-03-13
US10611777B2 (en) 2020-04-07
CL2017000682A1 (es) 2017-10-30
US20170253618A1 (en) 2017-09-07
KR20170048598A (ko) 2017-05-08
US10208066B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
GT201600123A (es) Inhibidores de syk
EA201692176A1 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
MX390051B (es) Antagonistas de ep4.
CL2017000659A1 (es) Inhibidores de histona desmetilasa
EA201692470A1 (ru) Фармацевтические комбинации
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa